PharmiWeb.com - Global Pharma News & Resources
05-Oct-2022

Global Oncology Based In-Vivo CRO Market Report 2022: Rising Outsourcing from Pharma Companies Driving Growth - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Oncology Based In-Vivo CRO Market Analysis, By Model, By Indication, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.


The oncology based in-vivo CRO market size is estimated to be USD 998.96 million in 2021 and is expected to witness a CAGR of 8.75% during the forecast period 2022-2029. The rising frequency with which big pharmaceutical companies outsource their R&D operations and increasing CROs' demand are projected to drive the market growth in near future. However, increased cost of cancer medications and their negative side effects are expected to restrain the market growth.

Segmentation: Oncology Based In-Vivo CRO Market Report 2021-2029 Model (Revenue, USD Million)

  • Xenograft
  • Syngeneic model

Indication (Revenue, USD Million)

  • Solid Tumors
  • Blood Cancer

By Region (Revenue, USD Million)

North America

  • U.S
  • Canada

Europe

  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM

Middle East & Africa

  • South Africa
  • GCC
  • Rest of MEA

Key Topics Covered:

1. Research Methodology

2. Introduction: Oncology Based In-Vivo CRO

3. Executive Summary

4. Market Dynamics

5. Market Environment Analysis

6. COVID-19 Impact Analysis: Oncology Based In-Vivo CRO Market

7. Market Analysis by Model

8. Market Analysis by Indication

9. Regional Market Analysis

10. North America Oncology Based In-Vivo CRO Market

11. Europe Oncology Based In-Vivo CRO Market

12. Asia Pacific Oncology Based In-Vivo CRO Market

13. Latin America Oncology Based In-Vivo CRO Market

14. MEA Oncology Based In-Vivo CRO Market

15. Competitor Analysis

16. Company Profiles

17. Conclusion & Recommendations

Companies Mentioned

  • Toxikon Inc.
  • Biosciences
  • ICON Plc
  • Covance
  • Charles River Laboratory (CRL)
  • Crown Bioscience
  • Eurofins Scientific
  • Taconic
  • The Jackson Laboratory
  • WuXi AppTec

For more information about this report visit https://www.researchandmarkets.com/r/43l4l1


Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 05-Oct-2022